Peter Johnson

Dr. Peter Johnson, a general and plastic surgeon, practiced reconstructive surgery for ten years at the University of Pittsburgh, where he founded and was the first President of the Pittsburgh Tissue Engineering Initiative. Subsequent roles included: co-founder and CEO of Tissue Informatics; EVP of Life Sciences, CMO and CBO of Icoria; EVP of Entegrion, Inc.; VP, R&D and Medical and Scientific affairs of Vancive Medical Technologies, an Avery Dennison business.

In addition to his work with MicroCures, Dr. Johnson also serves as President and CEO of Scintellix, LLC and co-founding Principal of MedSurgPI, LLC, and CEO of Beacon Biotherapeutics. He has chaired the Plastic Surgery Research Council and has been the President of the Pennsylvania Biotechnology Association and the Tissue Engineering Society, International (now TERMIS).

He serves on the board of the Transverse Myelitis Association, the Industrial Advisory Board of the UNC/NC State Joint Program in Bioengineering, the Industrial Technology Advisory Board of the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center, the board of the North Carolina Tissue Engineering and Regenerative Medicine Society, the board of Plakous Therapeutics, Inc., the board of Opsepio Therapeutics, Inc., the board of CellX Technology, and is Chairman of the Advisory Board for SonoVol, LLC.

He is an Adjunct Professor of Biomedical Engineering at the University of North Carolina at Chapel Hill, of Biomedical Engineering at NC State University and Duke University, and of Regenerative Medicine at Wake Forest University School of Medicine. Dr. Johnson received his undergraduate degree from the University of Notre Dame and earned an M.D. from SUNY Upstate Medical University.